High-throughput drug screening identifies EGFR/MAPK pathway targeting sensitivities in organoid models of ovarian carcinosarcoma
OCS is the most aggressive, drug-resistant gynaecological malignancy and eribulin-based combination therapies, particularly triple combination therapies, have the potential to improve patient outcomes.
Authors
- Matthew J. Wakefield (ORCID: https://orcid.org/0000-0001-6624-4698)
- Sally Beard
- Anthony Hadla (ORCID: https://orcid.org/0000-0003-4668-9408)
- Kate Jarman
- Holly E. Barker (ORCID: https://orcid.org/0000-0002-9350-5520)
- Dmitri Mouradov (ORCID: https://orcid.org/0000-0001-8149-816X)
- Anthony T. Papenfuss (ORCID: https://orcid.org/0000-0002-1102-8506)
- Gayanie Ratnayake (ORCID: https://orcid.org/0000-0001-6002-4619)
- Jocelyn Sietsma Penington (ORCID: https://orcid.org/0000-0003-1561-0074)
- Genevieve Dall (ORCID: https://orcid.org/0000-0001-6205-7342)
- Elizabeth L. Kyran (ORCID: https://orcid.org/0000-0002-9762-6127)
- Chloe Neagle
- Tim Blackmore (ORCID: https://orcid.org/0009-0001-2879-5154)
- Clare L. Scott
- Andrew Jarratt
- Ratana Lim
- Kristy Shield-Artin
- Andrew Farrell
- Tao Tan
- Rachael Taylor
- Cassandra J. Vandenberg
Institutions
- Royal Women's Hospital (AU)
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Peter MacCallum Cancer Centre (AU)
- Cancer Research UK Cambridge Center (GB)
- Victorian Comprehensive Cancer Centre (AU)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1186/s13046-025-03629-8
- Primary Topic
- Uterine Myomas and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00